Literature DB >> 28493815

The biology of JC polyomavirus.

Benedetta Assetta1, Walter J Atwood1.   

Abstract

JC polyomavirus (JCPyV) is the causative agent of a fatal central nervous system demyelinating disease known as progressive multifocal leukoencephalopathy (PML). PML occurs in people with underlying immunodeficiency or in individuals being treated with potent immunomodulatory therapies. JCPyV is a DNA tumor virus with a double-stranded DNA genome and encodes a well-studied oncogene, large T antigen. Its host range is highly restricted to humans and only a few cell types support lytic infection in vivo or in vitro. Its oncogenic potential in humans has not been firmly established and the international committee on oncogenic viruses lists JCPyV as possibly carcinogenic. Significant progress has been made in understanding the biology of JCPyV and here we present an overview of the field and discuss some important questions that remain unanswered.

Entities:  

Keywords:  HIV/AIDS; JCPyV; PML; immune response; multiple sclerosis; virus receptors

Mesh:

Substances:

Year:  2017        PMID: 28493815     DOI: 10.1515/hsz-2016-0345

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  36 in total

1.  Detecting viral genomes in the female urinary microbiome.

Authors:  Andrea Garretto; Krystal Thomas-White; Alan J Wolfe; Catherine Putonti
Journal:  J Gen Virol       Date:  2018-06-11       Impact factor: 3.891

2.  Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.

Authors:  Claudia Piu; Gabriele Ibba; Diego Bertoli; Ruggero Capra; Elena Uleri; Caterina Serra; Luisa Imberti; Antonina Dolei
Journal:  J Neurovirol       Date:  2019-08-29       Impact factor: 2.643

3.  Not a Disease of the Past: A Case Series of Progressive Multifocal Leukoencephalopathy in the Established Antiretroviral Era.

Authors:  Nathan A Summers; Colleen F Kelley; Wendy Armstrong; Vincent C Marconi; Minh Ly Nguyen
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-03       Impact factor: 2.205

4.  Susceptibility of Primary Human Choroid Plexus Epithelial Cells and Meningeal Cells to Infection by JC Virus.

Authors:  Bethany A O'Hara; Gretchen V Gee; Walter J Atwood; Sheila A Haley
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

5.  CD8 T Cells and STAT1 Signaling Are Essential Codeterminants in Protection from Polyomavirus Encephalopathy.

Authors:  Taryn E Mockus; Colleen S Netherby-Winslow; Hannah M Atkins; Matthew D Lauver; Ge Jin; Heather M Ren; Aron E Lukacher
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

6.  Adipocyte Plasma Membrane Protein (APMAP) promotes JC Virus (JCPyV) infection in human glial cells.

Authors:  Sheila A Haley; Bethany A O'Hara; Walter J Atwood
Journal:  Virology       Date:  2020-06-07       Impact factor: 3.616

7.  Bacteriophages of the Urinary Microbiome.

Authors:  Taylor Miller-Ensminger; Andrea Garretto; Jonathon Brenner; Krystal Thomas-White; Adriano Zambom; Alan J Wolfe; Catherine Putonti
Journal:  J Bacteriol       Date:  2018-03-12       Impact factor: 3.490

8.  JC Polyomavirus Infection Reveals Delayed Progression of the Infectious Cycle in Normal Human Astrocytes.

Authors:  Michael P Wilczek; Jeanne K DuShane; Francesca J Armstrong; Melissa S Maginnis
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

Review 9.  Viral Interactions with Adaptor-Protein Complexes: A Ubiquitous Trait among Viral Species.

Authors:  Ivana Strazic Geljic; Paola Kucan Brlic; Lucija Musak; Dubravka Karner; Andreja Ambriović-Ristov; Stipan Jonjic; Peter Schu; Tihana Lenac Rovis
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

10.  Colorectal Carcinoma Affected Patients Are Significantly Poor Responders Against the Oncogenic JC Polyomavirus.

Authors:  Elena Torreggiani; Ilaria Bononi; Silvia Pietrobon; Elisa Mazzoni; Giovanni Guerra; Carlo Feo; Fernanda Martini; Mauro Tognon
Journal:  Front Immunol       Date:  2021-05-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.